12-Week, Double-Blind, Placebo-Controlled Study of 20 and 60 mg/Day Istradefylline in Parkinson's Disease Patients on Levodopa/Carbodopa12-Week, Double-Blind, Placebo-Controlled, Randomized Study of the Efficacy of 40 mg/Day KW-6002 in Parkinson's Disease Patients on Levodopa/CarbidopaA Phase 2b Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking LevodopaA 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's DiseaseA Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease (2004-11-30)A Study of Istradefylline (KW-6002) for the Treatment of Parkinson's Disease in Patients Taking Levodopa (2005-04-30)
P4844
description
Arzneistoff
@de
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Istradefilin
@sh
Istradefilin
@sr
Istradefilin
@sr-el
Istradefyllin
@de
Istradefylline
@vi
istradefylline
@en
Истрадефилин
@sr-ec
イストラデフィリン
@ja
type
label
Istradefilin
@sh
Istradefilin
@sr
Istradefilin
@sr-el
Istradefyllin
@de
Istradefylline
@vi
istradefylline
@en
Истрадефилин
@sr-ec
イストラデフィリン
@ja
altLabel
C20H24N4O4
@sr
Istradefylline
@de
Istradefylline
@sr
KW-6002
@sr
prefLabel
Istradefilin
@sh
Istradefilin
@sr
Istradefilin
@sr-el
Istradefyllin
@de
Istradefylline
@vi
istradefylline
@en
Истрадефилин
@sr-ec
イストラデフィリン
@ja
P129
P486
P592
P6366
P646
P661
P662
P665
P683
P2017
CCN1C2=C(C(=O)N(C1=O)CC)N(C(=N2)/C=C/C3=CC(=C(C=C3)OC)OC)C
P2067
384.179755
P231
155270-99-8
P232
P233
CCN1C2=C(C(=O)N(C1=O)CC)N(C(=N2)C=CC3=CC(=C(C=C3)OC)OC)C
P234
1S/C20H24N4O4/c1-6-23-18-17(19 ...... 28-5/h8-12H,6-7H2,1-5H3/b11-9+
P235
IQVRBWUUXZMOPW-PKNBQFBNSA-N
P2566
100.230.117
P274
C₂₀H₂₄N₄O₄